Brilinta sales 2020

Annual Sales of Brilinta reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Otezla* generated $617 million of sales in the fourth quarter of 2020, and $2.2 billion for the full year. The Brilinta Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Brilinta Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional … Basel, January 26, 2021 – commenting on 2020 results, Vas Narasimhan, CEO of Novartis, said: "Novartis delivered a solid performance in 2020 across our strategic priorities, despite the challenges of COVID-19. Operationally, we grew sales and continued to improve core operating margins for Innovative Medicines. This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Brilinta sales, projected growth trends, production technology, application and end-user industry. Enbrel benefited from ~$115M in favorable changes to estimated sales deductions in Q1 2020 which will unfavorably impact the year-over-year comparison in Q1 2021. AMGEVITA™ (adalimumab) increased 45% year-over-year for the fourth quarter, and increased 54% for the full year driven by volume growth, partially offset by lower net selling price. How many physicians were reached by Brilinta through reportable promotional activity in 2020 and how does this compare to its peer set in the Stroke Prevention market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity? How does AstraZeneca's depth of coverage vary within key … Brilinta maxed out its sales at $1.6 billion in 2020, but its momentum was slowed by results from two studies in 2016. In one, Brilinta failed to top aspirin in preventing strokes. Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while … Boehringer Ingelheim generated net sales of around €2.2 billion ($2.46 billion) in the Animal Health business area during the first six months of 2020 compared with €2.1 billion ($2.35 billion) in January-June 2019. Sales of Nexgard grew 12.2 percent to €446 million ($499 million). Brilinta Market Insights The global Brilinta market size was valued at USD 1.85 billion in 2025. The market is projected to grow from USD 1.98 billion in 2026 to USD 3.42 billion by 2034, exhibiting a CAGR of 7.1% during the forecast period. Brilinta, the trade name for ticagrelor, is an antiplatelet medication developed by AstraZeneca and primarily used to prevent cardiovascular events such … The Brilinta market was valued at $6.8 billion in 2025 and is projected to reach $11.2 billion by 2034, growing at 5.8% CAGR. Global analysis of antiplatelet therapy market trends. The Brilinta market size, estimations, and forecasts are provided in terms of sales volume (k pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Brilinta market comprehensively. BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1)] . The Brilinta Market Analysis market report covers financials, market share, SWOTs, and responses to Tariffs, while providing global, regional, and country-level forecasts supported by value chain, patent analysis, and a competitive matrix serving as a key resource for stakeholders and investors. BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1 … The Brilinta Market was valued at USD 1,506.2 million in 2024 and is projected to reach USD 2,329.1 million by 2032, growing at a CAGR of 5.6% during the forecast period. AstraZeneca's Brilinta won its coveted stroke-prevention nod. Will it be enough to boost long-term sales? By Angus Liu Nov 6, 2020 11:18am Ischemic Stroke stroke AstraZeneca Brilinta Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. Brilinta Market Opportunities in e-commerce distribution are increasing due to a 48% rise in online prescription orders since 2020. More than 40% of long-term cardiac patients prefer home delivery services for chronic therapy management. To focus on the key Brilinta Market manufacturers, defining, describing, and analyzing their sales volume, value, market share, market competition landscape, SWOT analysis, and development plans. To analyze the Brilinta Market with respect to individual growth trends, prospects, and their contribution to the total market. Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Global Brilinta Market size was valued at USD 2.14 Bn in 2025, and the Brilinta Market revenue is expected to grow at a CAGR of 9% from 2026 to 2034, reaching nearly USD 4.66 Bn. Brilinta Market Overview The global Brilinta Market size is projected to grow from USD 2248.57 million in 2026 to USD 2440.69 million in 2027, reaching USD 4705.16 million by 2035, expanding at a CAGR of 8.55% during the forecast period. Brilinta peaked at $1.59 billion globally in 2020. Its growth was further hampered by COVID-19's impact on cardiovascular hospitalizations and China's volume-based procurement (VBP) program, which pressured prices. Global Brilinta Market Size And Forecast The Global Brilinta Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027. Chapter 3, the Brilinta competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Brilinta breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031. Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. The global Brilinta market size is expected to reach $ million by 2031, rising at a market growth of %CAGR during the forecast period (2025-2031). It's a blow to AZ, particularly after Brilinta had begun to gather speed. Stepped-up marketing and one new indication helped boost sales by 48% for the first half of this year. FDA approval history for Brilinta (ticagrelor) used to treat Acute Coronary Syndrome, Coronary Artery Disease, Cardiovascular Risk Reduction, Ischemic Stroke, Prophylaxis. Supplied by AstraZeneca Brilinta sales of $1,581 million, representing growth of 20% (23% at CER), due to continued patient uptake for acute coronary syndromes and post-myocardial infarction Brilinta Brilinta (ticagrelor) is an oral, reversible, direct-acting P2Y12 receptor antagonist that works by inhibiting platelet activation. Brilinta, together with aspirin, has been shown to significantly reduce the risk of MACE defined as myocardial infarction (MI, heart attack), stroke or CV death, in patients with ACS or a history of MI. The global market for Brilinta was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period. Brilinta's revenue trajectory therefore depends on international sales, continued use in higher-risk patients, label breadth, physician preference versus generic clopidogrel, and the speed of generic launches. What is Brilinta and how does it generate revenue? Results for blood thinning treatment boost prospects for AstraZeneca's sales targets AstraZeneca is one of the day's bigger risers in a falling market after a positive update on its Brilinta … In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Brilinta, the top five companies hold a share nearly %. In terms of sales (consumption) side, this report focuses on the sales of Brilinta by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2029.